期刊文献+

拉帕替尼合成工艺研究 被引量:11

Practical synthesis of lapatinib
下载PDF
导出
摘要 报道了拉帕替尼二对甲苯磺酸盐一水合物(1)的合成工艺研究。以6-碘喹唑啉-4-酮(3)为起始原料,依次经氯化反应(收率88%)、与5-甲酰基呋喃-2-硼酸的Suzuki偶联反应(收率96%)、与2-(甲砜基)乙胺的还原胺化(收率94%)、与一水合对甲苯磺酸成盐(收率87%)和四氢呋喃-水(8∶2)结晶(收率70%)等5步操作制备目标产物1,总收率48%。各中间体和目标产物经1HNMR、13CNMR、ESI-MS表征。在工艺优化中革除了柱色谱及对环境不友好的过量氯化剂、含卤溶剂,采用易于回收的非均相催化剂钯炭替代昂贵和难以处理的均相催化剂。所研制的合成工艺路线各步收率均较高,而且操作简便,无需特殊试剂和条件,预期适合工业化生产的要求。 This paper deals with the development of a practical process for lapatinib tosylate monohydrate( 1), a molecule-targeted antitumor agent. The target product 1 was synthesized from commercially available 6-iodoquinazolin-4-one(3) in a five-step process with an overall yield of 48% via chlorination(88% yield), palladium car- bon catalyzed Suzuki coupling with 5-formyl-2-furylboronic acid(96% yield), reduetive amination with 2-( meth- ylsulfone) ethylamine(94% yield), salt formation with p-toluenesulfonie acid monohydrate(87% yield), and final crystallization from THF-water ( 8 : 2) (70% yield). The intermediates and the target product were characterized by melting points, I H NMR, 13C NMR, and ESI-MS. During our optimized process, chromatography, large excess of chlorinating agent and halogenated solvent that are unfriendly to the environment were all removed; expensive and difficult-to-handle homogeneous catalyst was successfully substituted with heterogeneous catalyst palladium carbon which could be recovered easily. In conclusion, this streamlined synthetic process of lapatinib tosylate mono- hydrate(1) highlights excellent yield in almost every procedure, ease of operation, robustness, as well as green chemistry, and thus should be amenable to large-scale production.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2010年第4期317-320,共4页 Journal of China Pharmaceutical University
基金 国家"重大新药创制"科技重大专项资助项目(No.2009ZX09301-007) 上海市基础研究重点项目(No.09JC1413200)~~
关键词 拉帕替尼 酪氨酸激酶抑制剂 合成工艺 分子靶向治疗 抗肿瘤药 lapatinib tyrosine kinase inhibitor synthetic process molecule-targeted therapy antitumor agents
  • 相关文献

参考文献10

  • 1Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors [ J ]. J Med Chem,2007,50 ( 3 ) :409 - 424.
  • 2Johnston SRD, Leafy A. Lapatinib:a novel EGFR/HER2 tyrosine kinase inhibitor for cancer[J].Drugs Today,2006,42 (7) : 441 - 453.
  • 3Petrov KG, Zhang Y-M, Carter M,et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series [ J ]. Bioorg Med Chem Lett,2006,16 ( 17 ) : 4 686 -4 691.
  • 4季兴,王武伟,许贯虹,李飞,姚社春.拉帕替尼的合成[J].中国医药工业杂志,2009,40(11):801-804. 被引量:13
  • 5Sardon T, Cottin T, Xu J, et al. Development and biological evaluation of a novel aurora A kinase inhibitor[ J]. Chembiochem, 2009,10(3) :464 - 478.
  • 6Wallace E, Vile S, Zhao Q, et al. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors: US,7488823 [ P]. 2009- 02-10[2010-03-16].
  • 7Hudson AT, Topolov G, Barraclough P, et al. Substituted heteroaromatic compounds and their ues in medicine: WO,9609294 [ P ]. 1996-03-28 [ 2010-03-161.
  • 8Nishino S, Hirotsu K, Shima H, et al. Process for producing 4-aminoquinazoline compound : US, 2005130995 [ P ]. 2005-06-16 [2010-03-16].
  • 9McClure MS, Osterhout MH, Roschangar F, et al. A practical one-pot synthesis of 5-aryl-2-furaldehydes [ J ]. Synthesis, 2001, (11):1 681 -1 685.
  • 10McClure MS, Osterhout MH, Roschangar F, et al. Quinazoline ditosylate salt compounds : US, 7157466 [ P ]. 2007-01-02 [ 2010- 03-16].

二级参考文献10

  • 1Petrov KG, Zhang YM, Carter M, et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series [J]. Bioorg Med Chem Lett, 2006, 16(17): 4686-4691.
  • 2Soghra K, Didier P, Alexander M, et al. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase [J]. Bioorg Med Chem, 2005, 13 (7) : 2637-2649.
  • 3Balcom D, Furst A. Reductions with hydrazine hydrate catalyzed by Raney nickel. I. Aromatic nitro compounds to amines [J]. J Am Chem Soc, 1953, 75(17): 4334.
  • 4Wissner A, Fraser HL, Ingalls CL, et al. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incoiporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2 [J]. Bioorg Med Chem, 2007, 15(11): 3635-3648.
  • 5Fischer RW, Misun M. Large-scale synthesis of a pyrrolo[2,3-d]pyrimidine via Dakin-West reaction and Dimroth rearrangement [J]. Org Proc Res Dev, 2001, 5 (6) : 581-586.
  • 6Mcclure MS, Osterhout MH, Roschangar F, et al. Quinazoline ditosylate salt compounds: WO, 2002002552[P]. 2002-01-10.
  • 7Abdel-Magid AF, Carson KG, Harris BD, et al. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride studies on direct and indirect reductive amination procedures [J]. J Org Chem, 1996, 61 (11) : 3849-3862.
  • 8Byung HH, Dae HS, Sung YC. Graphite catalyzed reduction of aromatic and aliphatic nitro compounds with hydrazine hydrate [J]. Tetrahedron Lett, 1985, 26 (50): 6233-6234.
  • 9刘斯婕,胡春.拉帕替尼(lapatinb)[J].中国药物化学杂志,2007,17(5):333-333. 被引量:7
  • 10赵胜军,朱珠.新型双向酪氨酸激酶抑制剂——拉帕替尼[J].中国药学杂志,2008,43(13):1037-1038. 被引量:10

共引文献12

同被引文献56

引证文献11

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部